Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
暂无分享，去创建一个
M. Morris | A. Tolcher | A. Armour | D. Petrylak | O. Sartor | N. Vogelzang | M. Gordon | H. Babiker | Michael D. Groaning | A. Robarts